Skip to main content
. Author manuscript; available in PMC: 2022 Jun 27.
Published in final edited form as: Clin Cancer Res. 2021 Jun 17;27(17):4757–4767. doi: 10.1158/1078-0432.CCR-21-0903

Figure 2.

Figure 2.

A, Rises in levels of circulating cytokines or chemokines on-treatment compared with pre-treatment samples, showing nine cytokines or chemokines with highly significant differences (P < 0.001). In addition, levels of CD40 and the ligand of the cabiralizumab target, MCSF, were also significantly higher after treatment. B, Nine cytokines/chemokines, CD40, and MCSF, the ligand of cabiralizumab, were significantly increased (P < 0.001) by rank value after two cycles of therapy (samples available from 22/26 patients) compared to pre-treatment levels (samples available from 26/26 patients).